(may affect up to 1 in 10 people)<\/em><\/p>\n\n\n\nBlood infection<\/p>\n\n\n\n
Fever with low neutrophil count (a type of white blood cell )<\/p>\n\n\n\n
Reduced platelet count<\/p>\n\n\n\n
Allergic reaction<\/p>\n\n\n\n
Dehydration<\/p>\n\n\n\n
Taste changes<\/p>\n\n\n\n
Muscle weakness due to damage to motor nerves, especially in the arms and legs<\/p>\n\n\n\n
Loss of sensation, burning pain, and unsteady gait due to damage to sensory nerves<\/p>\n\n\n\n
Dizziness<\/p>\n\n\n\n
Inflammation or swelling of the conjunctiva ( membrane at the end of the eyelids and covering the eyes white)<\/p>\n\n\n\n
Dry eyes<\/p>\n\n\n\n
Tear-filled eyes<\/p>\n\n\n\n
Dried conjunctiva ( membrane at the outer part of the eyelids and covering the eyes white and cornea (the clear layer that protects the iris and pupil )<\/p>\n\n\n\n
Swollen eyelids<\/p>\n\n\n\n
Eye problems, such as dryness, tearing, irritation, and\/or pain.<\/p>\n\n\n\n
Heart failure (a condition that affects the pumping power of your heart muscle)<\/p>\n\n\n\n
Irregular heartbeat<\/p>\n\n\n\n
Indigestion<\/p>\n\n\n\n
Constipation<\/p>\n\n\n\n
Abdominal pain<\/p>\n\n\n\n
Liver: increase in the substances in the blood produced by the liver<\/p>\n\n\n\n
Increased skin pigmentation<\/p>\n\n\n\n
Itching<\/p>\n\n\n\n
Rash on the body therewith red marks<\/p>\n\n\n\n
Hair loss<\/p>\n\n\n\n
Hives<\/p>\n\n\n\n
Kidney failure<\/p>\n\n\n\n
Decreased renal function<\/p>\n\n\n\n
Fever<\/p>\n\n\n\n
Pain<\/p>\n\n\n\n
Excess fluid in body tissue, causing swelling<\/p>\n\n\n\n
Chest pain<\/p>\n\n\n\n
Inflammation and ulceration of the mucous membranes that line the digestive tract
<\/p>\n\n\n\n
Uncommon <\/em>(may affect up to 1 in 100 people)<\/em><\/p>\n\n\n\nReduction in the number of red and white blood cells and platelets<\/p>\n\n\n\n
Stroke<\/p>\n\n\n\n
Type of stroke when an artery to the brain is blocked<\/p>\n\n\n\n
Bleeding inside the skull<\/p>\n\n\n\n
Angina (Chest pain caused by decreased blood flow to the heart)<\/p>\n\n\n\n
Myocardial infarction<\/p>\n\n\n\n
Narrowing or blockage of the coronary arteries<\/p>\n\n\n\n
Elevated heart rate<\/p>\n\n\n\n
Reduced blood distribution to the limbs<\/p>\n\n\n\n
Blood clots in the pulmonary blood vessels ( pulmonary embolism )<\/p>\n\n\n\n
Inflammation and scarring of the lungs with respiratory problems<\/p>\n\n\n\n
Passage of bright red blood from the anus<\/p>\n\n\n\n
Bleeding in the gastrointestinal tract<\/p>\n\n\n\n
Broken intestine<\/p>\n\n\n\n
Inflammation of the esophageal mucosa (esophagus)<\/p>\n\n\n\n
Colitis ( inflammation of the wall of the colon, which may be accompanied by bleeding from the intestines or rectum (seen only in combination with cisplatin)<\/p>\n\n\n\n
Inflammation, edema, erythema, and erosion of the mucosal surface of the esophagus caused by radiation therapy<\/p>\n\n\n\n
Inflammation of the lung caused by radiation therapy
<\/p>\n\n\n\n
Rare (may affect up to 1 in 1,000 people)<\/em><\/p>\n\n\n\nDestruction of red blood cells<\/p>\n\n\n\n
Anaphylactic shock (severe allergic reaction )<\/p>\n\n\n\n
Inflammatory conditions of the liver<\/p>\n\n\n\n
Redness of the skin<\/p>\n\n\n\n
Skin rash that may occur on skin that has previously been exposed to radiation therapy.
<\/p>\n\n\n\n
Very rare (may affect up to 1 in 10,000 people)<\/em><\/p>\n\n\n\nInfection s skin and soft tissue s<\/p>\n\n\n\n
Stevens-Johnson syndrome (a type of severe reaction to skin and mucous membranes that can be life-threatening)<\/p>\n\n\n\n
Toxic epidermal necrolysis (a type of severe skin reaction that can be life-threatening)<\/p>\n\n\n\n
An autoimmune condition that results in skin rashes and blisters on legs, arms, and abdomen<\/p>\n\n\n\n
Inflammation of the skin characterized by the presence of bullous conditions with fluid-filled blistering)<\/p>\n\n\n\n
Fragile skin, blisters, and erosion as well as scarring of the skin<\/p>\n\n\n\n
Redness, pain, and swelling mainly in the lower legs<\/p>\n\n\n\n
Inflammation of the skin and fat under the skin (pseudo cellulite)<\/p>\n\n\n\n
Inflammation of the skin ( dermatitis )<\/p>\n\n\n\n
Skin that becomes inflamed, itchy, red, cracked, and rough<\/p>\n\n\n\n
Intense itchy spots
<\/p>\n\n\n\n
Has been reported (occurs in an unknown number of users)<\/em><\/p>\n\n\n\nA form of diabetes that is primarily based on kidney pathology<\/p>\n\n\n\n
Kidney disorder involving tubular epithelial cells (which form renal tubules) death.
<\/p>\n\n\n\n
You may get any of these symptoms and\/or ailments. If you start to experience any of these side effects, talk to your doctor as soon as possible.
<\/p>\n\n\n\n
If you have any side effects, talk to your doctor.
<\/p>\n\n\n\n
If you get any side effects, talk to your doctor or pharmacist. This also applies to any side effects not mentioned in this information.<\/p>\n\n\n\n
5. How to store ALIMTA<\/h2>\n\n\n\n
Keep this medicine out of the sight and reach of children.<\/p>\n\n\n\n
Do not use this medicine after the expiry date which is stated on the bottle label and carton.<\/p>\n\n\n\n
This medicine has no special storage instructions.
<\/p>\n\n\n\n
Dissolved drug and infusion solution: The drug should be used immediately. Chemical and physical shelf life for 24 hours in a refrigerator has been demonstrated for the reconstituted stock solution and the infusion solution of pemetrexed if reconstituted according to the instructions.
<\/p>\n\n\n\n
This medicine is for single use only. Any unused solution should be disposed of in accordance with local requirements.<\/p>\n\n\n\n
6. Contents of the packaging and other information<\/h2>\n\n\n\nContent declaration<\/h2>\n\n\n\n
The active substance is pemetrexed.
<\/p>\n\n\n\n
ALIMTA 100 mg: One vial contains 100 mg pemetrexed (as disodium pemetrexed).<\/p>\n\n\n\n
ALIMTA 500 mg: One vial contains 500 mg of pemetrexed (as disodium pemetrexed).
<\/p>\n\n\n\n
After reconstitution, the solution contains 25 mg \/ ml pemetrexed. Further dilution of healthcare professionals is required before injection.
<\/p>\n\n\n\n
The other ingredients are mannitol, hydrochloric acid, and sodium hydroxide.<\/p>\n\n\n\n
What the medicine looks like and the contents of the pack<\/h2>\n\n\n\n
ALIMTA is a powder for concentrate for solution for infusion in a vial. It is a white to light yellow or greenish-yellow, lyophilized powder.<\/p>\n\n\n\n
Available in packs of 1 bottle.
<\/p>\n\n\n\n
Not all pack sizes may be marketed.<\/p>\n\n\n\n
Marketing Authorization Holder and Manufacturer<\/h2>\n\n\n\n
Eli Lilly Nederland BV, Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands<\/p>\n\n\n\n
Lilly France SAS, rue du Colonel Lilly, F-67640, Fegersheim, France
<\/p>\n\n\n\n
Contact the representative of the marketing authorization holder to find out more about this medicine:<\/p>\n\n\n\n
Further information on this medicine is available on the European Medicines Agency web site: http:\/\/www.ema.europa.eu.
<\/p>\n\n\n\n
This leaflet was approved by September 2020 at the latest<\/p>\n\n\n\n
The following information is intended for medical or healthcare professionals only<\/h2>\n\n\n\n
Instructions for use and handling and disposal<\/em><\/p>\n\n\n\n- Use aseptic technique during reconstitution and dilution of pemetrexed for intravenous infusion.<\/li>
- Calculate the dose and number of vials of ALIMTA required. Each vial contains an excess of pemetrexed to facilitate withdrawal of the amount indicated on the label.<\/li>
- ALIMTA 100 mg:Dissolve the powder in each vial (100 mg) in 4.2 ml of sterile sodium chloride 9 mg \/ ml (0.9%) solution without preservative . A solution containing 25 mg \/ ml pemetrexed is obtained.
ALIMTA 500 mg:
Dissolve the powder in each vial (500 mg) in 20 ml sterile sodium chloride 9 mg \/ ml (0.9%) solution without preservative . A solution containing 25 mg \/ ml pemetrexed is obtained.
Gently swirl the bottle until the powder is completely dissolved. The solution obtained is clear and varies in color from colorless to yellow or greenish-yellow without adversely affecting the quality of the product. The pH of the dissolved solution is between 6.6 and 7.8. Further dilution is required<\/strong>.<\/li>- The volume of reconstituted pemetrexed solution taken should be further diluted to 100 ml with sterile sodium chloride 9 mg\/ml (0.9%) solution without preservative and administered as an intravenous infusion over 10 minutes.<\/li>
- Pemetrexed infusion solutions, prepared as above, are compatible with administration kits and infusion bags are internally coated with polyvinyl chloride and polyolefin.
Pemetrexed is incompatible with diluents containing calcium, including the infusion fluids Ringer-lactate and Ringer’s solution.<\/li> - Drugs administered parenterally should be visually inspected for particulate matter and discoloration prior to administration. If particles are observed, the solution should not be administered.<\/li>
- Pemetrexed solutions are for single use only. Any unused product or waste material should be disposed of in accordance with local requirements.<\/li><\/ol>\n\n\n\n
Precautions for use in administration and administration:<\/strong> As with other potentially toxic anticancer medicinal products, caution should be exercised when handling and preparing infusion solutions containing pemetrexed. The use of gloves is recommended. If pemetrexed solution comes in contact with the skin, wash the skin immediately and thoroughly with soap and water. If pemetrexed solution comes in contact with mucous membranes, rinse thoroughly with water. Pemetrexed does not cause blisters. There is no specific antidote for the extravasation of pemetrexed. A few isolated cases of pemetrexed extravasation have been reported but were not considered serious by the investigator. Extravasation should be treated according to local practice as other non-blowing agents.<\/p>\n","protected":false},"excerpt":{"rendered":"ALIMTA is given together with cisplatin, another anti-cancer medicine, for the treatment of malignant pleural mesothelioma, a form of lung cancer, to patients who have not previously received anticancer medicine.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"categories":[2201,2200],"tags":[10985,10988,10012,10983,10984,10989,10987,10986,10013,10014],"class_list":["post-5186","post","type-post","status-publish","format-standard","hentry","category-a","category-medicines","tag-alimta","tag-alimta-powder","tag-pemetrexed","tag-pemetrexed-powder","tag-side-efects-of-pemetrexed","tag-side-effects-of-alimta","tag-what-alimta-is-used-for","tag-what-is-alimta","tag-what-is-pemetrexed","tag-what-pemetrexed-is-used-for"],"_links":{"self":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/5186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/comments?post=5186"}],"version-history":[{"count":5,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/5186\/revisions"}],"predecessor-version":[{"id":12874,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/5186\/revisions\/12874"}],"wp:attachment":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/media?parent=5186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/categories?post=5186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/tags?post=5186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}